Literature DB >> 8067757

Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.

J A Karlowsky1, G G Zhanel, R J Davidson, D J Hoban.   

Abstract

A novel, in vitro, pharmacodynamic comparison of single and divided daily dosing regimens of aminoglycosides is described. Experiments were conducted to evaluate the impact of gentamicin and tobramycin concentration on the time required for the MICs for five Pseudomonas aeruginosa strains to revert to their original values (MIC reversion time [MRT]) following single and multiple 2-h aminoglycoside exposures to 8 and 24 mg/liter. Single 2-h aminoglycoside exposures to 8 mg/liter produced culture MRTs (gentamicin, 21.5 +/- 4.0 h; tobramycin, 22.3 +/- 2.8 h) that were significantly (P < 0.05) shorter than those measured following identical exposures to 24 mg/liter (gentamicin, 28.9 +/- 3.8 h; tobramycin, 26.8 +/- 3.1 h). However, three sequential 2-h exposures to 8 mg/liter, one exposure every 8 h, produced MRTs following the third exposure (gentamicin, 68.1 +/- 5.2 h; tobramycin, 77.8 +/- 7.8 h) that were significantly longer (P < 0.005) than those determined following three 2-h exposures to 24 mg/liter, one exposure every 24 h (gentamicin, 36.1 +/- 3.0 h; tobramycin, 34.5 +/- 3.0 h). In addition, the once-daily exposure regimen to 24 mg/liter consistently produced cultures with significantly (P < 0.005) higher aminoglycoside concentration/MIC ratios compared with those for cultures reexposed to 8 mg/liter once every 8 h. These data support the concept of once-daily aminoglycoside dosing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067757      PMCID: PMC188170          DOI: 10.1128/AAC.38.5.1165

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides.

Authors:  J A Karlowsky; G G Zhanel
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

Review 2.  The postantibiotic effect: a review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  DICP       Date:  1991-02

3.  Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

Authors:  G L Daikos; G G Jackson; V T Lolans; D M Livermore
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  In vitro postantibiotic effect following repeated exposure to imipenem, temafloxacin, and tobramycin.

Authors:  B J McGrath; C R Marchbanks; D Gilbert; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

5.  In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth.

Authors:  J A Karlowsky; G G Zhanel; R J Davidson; S R Zieroth; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 6.  Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.

Authors:  G L Drusano
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 7.  Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?

Authors:  G G Zhanel; R E Ariano
Journal:  Ren Fail       Date:  1992       Impact factor: 2.606

8.  Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.

Authors:  G G Zhanel; J A Karlowsky; D J Hoban; R J Davidson
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

9.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

Review 10.  Pharmacodynamic factors of antibiotic efficacy.

Authors:  J C Rotschafer; R A Zabinski; K J Walker
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

View more
  4 in total

1.  Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.

Authors:  J G den Hollander; J W Mouton; M P van Goor; F P Vleggaar; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.

Authors:  Stefanie Hennig; Franziska Holthouse; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

3.  Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.

Authors:  Jean-Marie Conil; Bernard Georges; Stéphanie Ruiz; Thomas Rival; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin Pharmd; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

4.  In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa.

Authors:  J A Karlowsky; M H Saunders; G A Harding; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.